米国のシングルユースバイオリアクター市場：製品タイプ別、モジュールタイプ別、細胞タイプ別、用途別、エンドユーザー別、地域別、機会、予測、2018年～2032年

米国のシングルユースバイオリアクターの市場規模は、予測期間の2025年～2032年に17.98％のCAGRで拡大し、2024年の12億7,100万米ドルから2032年には47億7,104万米ドルに成長すると予測されています。生物製剤と個別化治療薬に対する需要の高まりが、米国市場におけるシングルユースバイオリアクターの採用に拍車をかけています。その柔軟性、交差汚染のリスク低減、低資本投資により、最新のバイオ生産に理想的なものとなっています。自動化と連続バイオプロセス技術の進歩は、スケーラビリティと効率性の向上におけるシングルユースバイオリアクターの役割をさらに増大させています。

例えば、2025年1月、Danaherはヘルスケア人工知能企業であるInnovaccer Inc.への戦略的投資を発表しました。この提携は、Danaherの診断技術とInnovaccerのAI主導型統合患者記録プラットフォームを統合することで患者の転帰を向上させ、精密医療と価値に基づくケアの導入を促進することを目的としています。

当レポートでは、米国のシングルユースバイオリアクター市場について調査し、市場の概要とともに、製品タイプ別、モジュールタイプ別、細胞タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 米国のシングルユースバイオリアクター市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 製品別
    • シングルユースバイオリアクターシステム
    • シングルユースメディアバッグ
    • シングルユースろ過アセンブリおよびアクセサリ
  • モジュールタイプ別
    • 撹拌タンクSUB
    • 波動誘起SUB
    • バブルカラムSUB
    • その他
  • 細胞タイプ別
    • 哺乳類細胞
    • 細菌細胞
    • 酵母細胞
    • その他
  • 用途別
    • バイオプロダクション
    • プロセス開発
    • 研究開発
  • エンドユーザー別
    • 製薬会社・バイオテクノロジー企業
    • 臨床研究機関
    • 学術研究機関
  • 地域別
    • 北東部
    • 中西部
    • 西部
    • 南部
  • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
• 2024年の市場マップ分析

第6章 バリューチェーン分析

第7章 サプライチェーン分析

第8章 輸出入分析

第9章 ポーターのファイブフォース分析

第10章 PESTLE分析

第11章 価格分析

第12章 市場力学

• 市場の促進要因
• 市場の課題

第13章 市場動向と発展

第14章 規制枠組みとイノベーション

第15章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Thermo Fisher Scientific Inc.
  • EMD Millipore Corporation
  • Sartorius Corporation
  • Danaher Corporation
  • Getinge AB
  • Eppendorf North America, Inc.
  • Avantor Inc.
  • Cellexus Limited
  • Entegris, Inc.
  • Celltainer Biotech BV

第16章 戦略的提言

第17章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Single-use Bioreactors Market, By Value, In USD Million, 2018-2032F
• Figure 2. United States Single-use Bioreactors Market, By Volume, In Units, 2018-2032F
• Figure 3. United States Single-use Bioreactors Market Share (%), By Product, 2018-2032F
• Figure 4. United States Single-use Bioreactors Market Share (%), By Type of Module, 2018-2032F
• Figure 5. United States Single-use Bioreactors Market Share (%), By Cell Type, 2018-2032F
• Figure 6. United States Single-use Bioreactors Market Share (%), By Application, 2018-2032F
• Figure 7. United States Single-use Bioreactors Market Share (%), By End-user, 2018-2032F
• Figure 8. United States Single-use Bioreactors Market Share (%), By Region, 2018-2032F
• Figure 9. By Product Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 10. By Type of Module Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 11. By Cell Type Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 12. By Application Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 13. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2024
• Figure 14. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024

United States single-use bioreactors market is projected to witness a CAGR of 17.98% during the forecast period 2025-2032, growing from USD 1271 million in 2024 to USD 4771.04 million in 2032. Growing demand for biologics and personalized therapeutics is fueling the adoption of single-use bioreactors in the United States market. Their flexibility, reduced risk of cross-contamination, and lower capital investment make them ideal for modern bioproduction. Advances in automation and continuous bioprocessing technologies further amplify their role in improving scalability and efficiency.

For instance, in January 2025, Danaher announced a strategic investment in Innovaccer Inc., a healthcare artificial intelligence company. This partnership aims to enhance patient outcomes by integrating Danaher's diagnostic technologies with Innovaccer's AI-driven unified patient records platform, facilitating the adoption of precision medicine and value-based care.

Rising Demand for Biopharmaceuticals and Personalized Medicines

The increasing demand for biopharmaceuticals and personalized medicine is significantly boosting the United States single-use bioreactors market. As healthcare providers and pharmaceutical manufacturers shift toward more targeted therapies such as monoclonal antibodies, gene therapies, and vaccines, the need for flexible and scalable bioreactor systems has grown. Single-use bioreactors are ideal for producing smaller, more customized batches while reducing cross-contamination risks and operational turnaround time. This demand is particularly evident in the development of advanced therapies such as antibody-drug conjugates (ADCs), which require precise and contamination-free production processes. The biopharma industry is also investing in smaller, decentralized facilities that can accelerate time-to-market for personalized treatments, which single-use systems can efficiently support. Moreover, regulatory bodies are promoting flexible production systems that can easily be validated and scaled. The integration of automation, data analytics, and smart monitoring in single-use bioreactors further enables more efficient and reproducible outcomes. Companies are now designing reactors tailored for specific therapeutic classes, supporting greater innovation in manufacturing. For instance, in September 2024, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, launched the Mobius ADC Reactor-specifically engineered to manufacture antibody-drug conjugates, addressing the growing demand for targeted cancer therapies.

Advancements in Bioprocessing Technologies

Technological advancements in bioprocessing are transforming the single-use bioreactors landscape, particularly in the United States market. Innovations such as continuous bioprocessing, perfusion systems, and improved sensor technologies are enabling more efficient, scalable, and cost-effective biopharmaceutical production. Single-use systems integrated with automation and advanced control platforms allow real-time monitoring and process optimization, which enhances reproducibility and ensures regulatory compliance. These developments are especially critical as the complexity of biologics increases, requiring highly controlled environments to maintain product integrity. Manufacturers are also prioritizing space-saving designs and modular systems, which make facility setup faster and more adaptable.

Furthermore, improvements in material sciences have enhanced the durability, sterility, and compatibility of disposable components, mitigating concerns about leachables or extractables. As companies aim to streamline product development timelines, scalable single-use bioreactors are becoming integral to both pilot and commercial production stages. These trends have made the United States a hub for innovation and adoption of next-generation bioreactors. For instance, in July 2024, Avantor launched two new high-performance reagents for gene therapy manufacturing: J.T. Baker Cell Lysis Solution and J.T. Baker Endonuclease. These reagents will improve the process efficiency and reduce the contamination risk.

Cost Efficiency and Lower Capital Investment

The usage of disposable bioreactors, known as single-use bioreactors, allows companies to minimize their expenses related to cleaning and sterilization operations. The cleaning process for traditional stainless-steel tanks requires substantial resources, including acidic solutions and steam sterilization. Without these steps, the investment expenditure can be reduced by approximately 40-50%. With the help of single-use bioreactors, manufacturers can quickly start their production activities without

incurring additional expenses while also optimizing their setup time to just hours. Additionally, the flexibility offered by single-use bioreactors allows manufacturers to adapt quickly to changing production needs, aiding them in avoiding the high costs associated with revalidating fixed systems. Thus, providing overall savings in labor, energy, and time to small-to-medium-scale biomanufacturing companies. In March 2025, Merck has opened a new USD 1 billion, 225,000-square-foot vaccine manufacturing facility in Durham, North Carolina. This state-of-the-art facility incorporates advanced technologies including data analytics and generative AI to enhance vaccine production.

Future Market Scenario (2025-2032F)

The United States single-use bioreactors market is poised for significant growth driven by increased biopharmaceutical production, the rising prevalence of chronic diseases, and a growing emphasis on cost-effective, flexible manufacturing solutions. The expansion of cell and gene therapies, along with personalized medicine, will continue to demand scalable and sterile environments provided by single-use systems. Furthermore, ongoing innovation in bioprocessing technologies, regulatory encouragement for agile production methods, and the presence of major industry players investing in R&D are expected to accelerate market adoption. The shift toward decentralized and modular biomanufacturing will further support widespread implementation of these bioreactors across the country.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of single-use bioreactors and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

In February 2025, Thermo Fisher Scientific entered into an agreement to acquire Solventum's Purification and Filtration business for USD 4.1 billion in cash. This acquisition will enhance Thermo Fisher's bioproduction capabilities, particularly in biologics manufacturing, by integrating Solventum's innovative filtration technologies. The deal is expected to close by the end of 2025.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Single-use Bioreactors Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
  • 5.1.2. By Volume
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Single-use Bioreactor Systems
      • 5.2.1.1.1. Up to 100L
      • 5.2.1.1.2. 101-1500L
      • 5.2.1.1.3. Above 1500L
    • 5.2.1.2. Single-Use Media Bags
      • 5.2.1.2.1. 2D Bags
      • 5.2.1.2.2. 3D Bags
    • 5.2.1.3. Single-Use Filtration Assemblies and Accessories
  • 5.2.2. By Type of Module
    • 5.2.2.1. Stirred-Tank SUBs
    • 5.2.2.2. Wave-Induced SUBs
    • 5.2.2.3. Bubble-Column SUBs
    • 5.2.2.4. Others
  • 5.2.3. By Cell Type
    • 5.2.3.1. Mammalian Cells
    • 5.2.3.2. Bacterial Cells
    • 5.2.3.3. Yeast Cells
    • 5.2.3.4. Others
  • 5.2.4. By Application
    • 5.2.4.1. Bioproduction
    • 5.2.4.2. Process Development
    • 5.2.4.3. Research and Development
  • 5.2.5. By End-user
    • 5.2.5.1. Pharmaceutical and Biotechnology Companies
    • 5.2.5.2. Clinical Research Organizations
    • 5.2.5.3. Academic and Research Institutes
  • 5.2.6. By Region
    • 5.2.6.1. Northeast
    • 5.2.6.2. Midwest
    • 5.2.6.3. West
    • 5.2.6.4. South
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product
  • 5.3.2. By Type of Module
  • 5.3.3. By Cell Type
  • 5.3.4. By Application
  • 5.3.5. By End-user
  • 5.3.6. By Region

6. Value Chain Analysis

7. Supply Chain Analysis

8. Import-Export Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Pricing Analysis

12. Market Dynamics

• 12.1. Market Drivers
• 12.2. Market Challenges

13. Market Trends and Developments

14. Regulatory Framework and Innovation

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. EMD Millipore Corporation
  • 15.3.3. Sartorius Corporation
  • 15.3.4. Danaher Corporation
  • 15.3.5. Getinge AB
  • 15.3.6. Eppendorf North America, Inc.
  • 15.3.7. Avantor Inc.
  • 15.3.8. Cellexus Limited
  • 15.3.9. Entegris, Inc.
  • 15.3.10. Celltainer Biotech BV

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer